$20.75
2.35% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

vTv Therapeutics, Inc. Class A Stock price

$20.75
+1.08 5.49% 1M
+5.29 34.22% 6M
+6.94 50.27% YTD
-7.46 26.44% 1Y
+2.60 14.34% 3Y
-98.45 82.59% 5Y
-414.85 95.24% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.50 2.35%
ISIN
US9183851057
Symbol
VTVT
Sector
Industry

Key metrics

Market capitalization $54.31m
Enterprise Value $24.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,218.00
P/S ratio (TTM) P/S ratio 2,715.50
P/B ratio (TTM) P/B ratio 6.84
Revenue growth (TTM) Revenue growth -98.30%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-25.06m
Free Cash Flow (TTM) Free Cash Flow $-23.66m
Cash position $31.06m
EPS (TTM) EPS $-3.01
P/E forward negative
Short interest 2.07%
Show more

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

Buy
100%

Financial data from vTv Therapeutics, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.02 0.02
98% 98%
100%
- Direct Costs 0.08 0.08
11% 11%
400%
-0.06 -0.06
107% 107%
-300%
- Selling and Administrative Expenses 13 13
8% 8%
66,350%
- Research and Development Expense 12 12
5% 5%
58,250%
-25 -25
6% 6%
-124,900%
- Depreciation and Amortization 0.08 0.08
11% 11%
400%
EBIT (Operating Income) EBIT -25 -25
6% 6%
-125,280%
Net Profit -19 -19
9% 9%
-93,450%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
GlobeNewsWire
one day ago
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development...
Neutral
GlobeNewsWire
5 days ago
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to in...
Neutral
GlobeNewsWire
6 days ago
Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has b...
More vTv Therapeutics, Inc. Class A News

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Paul Sekhri
Employees 23
Founded 2015
Website www.vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today